VivaGel® BV treatment clinical submission under rolling submission
Melbourne, Australia; 21 December 2017: Starpharma (ASX: SPL, OTCQX: SPHRY) today announced that it has completed the VivaGel® BV treatment clinical section of the NDA clinical module, which will be submitted to the FDA under Starpharma’s rolling submission on Friday 22 December 2017 (US time).
AGM Chairman’s address and CEO presentation
Chairman’s address and the CEO’s presentation to the 2017 Annual General Meeting of Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY).
NDA submission for Starpharma’s VivaGel® BV
|
BioSpectrum Asia reported on Starpharma’s NDA submission for VivaGel® BV, noting that Starpharma is one of the few Australian companies to take a locally developed product to this stage. |
NDA submission for VivaGel® BV in the US
Melbourne, Australia: Starpharma (ASX: SPL, OTCQX: SPHRY) today announced that its US New Drug Application (NDA) submission for VivaGel® BV for both treatment and prevention of BV has been lodged with the FDA through a rolling submission process.
Appendix 4C – Quarterly Cashflow Report
Starpharma today released its Appendix 4C – Quarterly Cashflow Report for the period ended 30 September 2017.
Starpharma receives TGA marketing approval for VivaGel® BV
|
Online financial news portal Finance News Network reported Starpharma received TGA marketing approval for VivaGel® BV, which is expected to be available in pharmacies in the new year under the Fleurstat™ brand. |
VivaGel® BV granted marketing approval in Australia
Starpharma today announced it has received Australian marketing approval from the Therapeutic Goods Administration (TGA) for VivaGel® BV, which is intended for treatment of bacterial vaginosis (BV).
Morgans Under the Microscope Interview featuring Dr Jackie Fairley
Morgans Under the Microscope series featured Starpharma's CEO, Dr Jackie Fairley, discussing a number of key milestones that are approaching and the licensing arrangements entered into with AstraZeneca.
Listen to the podcast (external link).
Shareholder Update October 2017
In this issue:
>> DEP® docetaxel achieves positive phase 1 results and commences phase 2
>> AZ presents first DEP® candidate AZD0466 – a Bcl2/xL inhibitor
>> Successful VivaGel® BV phase 3 results
>> Update on other internal DEP® candidates
>> Grant awarded to Starpharma-Monash
>> Starpharma and Peter Mac Cancer Centre awarded grant
>> FY17 Financial results; >$60M cash at 30 June
>> Annual Report and Annual General Meeting
>> Starpharma News & Events
Download: Shareholder Update October 2017 (pdf file, 1.3mb)